• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

This Pharma Presents a Potential 'Lose-Win' Situation for Patients and Investors

Two in five Americans are obese. Treatments that target obesity directly could be the next blockbuster pharma category.
By BRAD GINESIN
Jan 07, 2023 | 07:00 AM EST
Stocks quotes in this article: NVO, LLY

For years, we have dreamed of a true weight loss "pill" -- and now we need it more than ever.

Obesity affects more than 40% of adults in the United States and costs the health care system $173 billion annually. While we have drugs that treat the many consequences of obesity -- including diabetes, hypertension, high cholesterol, and various cardiovascular ailments -- a drug that targets obesity itself could be big winner.

Morgan Stanley makes a compelling argument that treatments that target obesity directly is the next blockbuster pharma category, with potential sales greater than $50 billion by 2030. This is why I believe Novo Nordisk (NVO) , the Danish pharmaceutical giant, is the stock to own to capitalize.

Historically, drugs that fight obesity have had significant side effects and limited efficacy, leading to restricted use and poor insurance reimbursement coverage. Novo and Ely Lilly (LLY)  have developed a new class of drugs to fight obesity, GLP-1 drugs, with a sound safety profile and demonstrably efficacious results. Patients taking Novo's drug Wegovy lost an average of 35 pounds, or about 15%, of their body weight, compared to six pounds, or roughly 2.5% of body weight, in the placebo group.

While weight loss results are noticeable, Novo and Lilly are studying the promise of the secondary benefits, such as reduced risk for heart attack, cardiovascular disease, strokes, and diabetes. Novo's "Select" trial has been running for over four years, with more than 15,000 participants, striving to determine the derivative effects of Novo's weight loss drug on reducing heart disease and stroke cases in obese patients. The study's conclusion and results are due in mid-2023 and could prove to be a major catalyst for the shares, if the results are statistically significant.

Morgan Stanley has an optimistic take on the trial's outcome, citing three reasons. First, there's an existing body of data demonstrating that bariatric surgery leads to lower risk of major adverse cardiovascular events. That procedure, however, is an extreme medical intervention, thus the data suggests that another effective weight loss treatment could also show similar benefits. Two, meta-analysis of GLP-1 drugs in non-diabetic obese and overweight people reads positive for supporting medical benefits. And, three, the GLP-1 drugs have demonstrated positive cardiovascular outcomes across a series of phase-3 trials in type-2 diabetes patients.

Novo also has a trial of oral semaglutide, a diabetes and obesity drug, with results expected in the first half of 2023.

Undoubtedly, waiting for trial results and for the health care system to recognize the benefits of obesity drugs is a big-picture idea with an uncertain outcome. Yet, it's too big to ignore. If Morgan's thesis is correct, treating obesity directly will medically be a far more appealing choice than treating the effects of obesity. Eli Lilly and Novo garner a premium valuation as they are potentially on the cusp of enormous growth in this category.

Novo Nordisk stock is only followed by a couple of domestic analysts. Cowen named Novo as one of its best ideas for 2023. The firm estimates top- and bottom-line compound growth from 2021-2027 to be 10%, justifying the premium multiple.

This past Sunday, "60 Minutes" profiled Novo's obesity weight-loss drug, Wegovy, noting its effectiveness for weight loss and the lack of health insurance coverage for desperate patients. Insurance companies have rejected coverage of Wegovy, at the cost of $1,300 per month, classifying it as a vanity drug akin to Viagra or Botox. Such high-profile media scrutiny of insurance companies will likely ease the way for medically beneficial reimbursement for this class of drugs.

Indeed, the promise of Novo's obesity drug is known, reflected in the stock's current high price-to-earnings of around 40, while Eli Lilly trades with a lofty 46 price-to-earnings. Even so, there's enough growth opportunity and upcoming catalysts to make for a worthwhile long-term investment, especially on pullbacks.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Ginesin had no position in any security mentioned.

TAGS: Investing | Stocks | Health Care Equipment & Services | Healthcare | Pharmaceuticals

More from Stocks

A Roundabout on Wall Street

James "Rev Shark" DePorre
Jun 8, 2023 4:25 PM EDT

The big caps turn out big again, with Apple, Microsoft and Nvidia at the wheel.

Ignore Carvana's Backseat Drivers

Ed Ponsi
Jun 8, 2023 1:09 PM EDT

I'll take a ride with CVNA, but I will wear my safety belt -- and know when to get out.

GameStop Needs to Unlock a Secret Door to a New Business

Stephen Guilfoyle
Jun 8, 2023 12:27 PM EDT

After another GME earnings blunder and change of players, I see the stock as this: pure speculation with a strong balance sheet. But I believe the company can find a way to the next level -- though it could get zapped before getting there.

Here's a Stock I'm Watching as the Rotation Gets Stuck in Reverse

James "Rev Shark" DePorre
Jun 8, 2023 11:46 AM EDT

I'm eyeing this biotech name as the Nasdaq 100 moves up -- again -- and small calls slip.

Want a Way Out of Taxes? Look to This Exchange-Traded Fund

Mark Abssy
Jun 8, 2023 11:30 AM EDT

If you are looking for completely tax-free income, check out the X-Square Municipal Income Tax-Free ETF.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:19 PM EDT CHRIS VERSACE

    AAP Podcast: This Company Is Not Going 'Solo'

    Listen in as I talk with the very diversified Solo...
  • 01:51 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Adjusting Your Trading Approach to Shifting Market...
  • 06:54 PM EDT CHRIS VERSACE

    AAP Podcast: A Tongue -- and a Market -- Twister: 'Get a Debt Deal Done'

    Listen in as the Action Alerts PLUS Podcast tackle...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login